Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTel Aviv University
About this trial
This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.
Eligibility criteria
Qualifiers
Diagnosis of PTSD according to DSM-5
Age 18 years and over
Eligible for CPT treatment at the National Center for Traumatic Stress and Resilience
Disqualifiers
Bipolar disorder, psychosis, neurological disorders
Drug Addiction
Parallel psychotherapy
Congenital or acquired anosmia.
Trial design
Treatments tested in this trial
- Cognitive Processing Therapy + Hexadecanal
- Hexadecanal - Molecule Distribution in the Therapy room
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Tel Aviv University
Lead sponsor
Weizmann Institute of Science
Collaborator
Source ClinicalTrials.gov